Fredun Pharmaceuticals Ltd

Y/e 31 Mar( In .Cr)	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Equity Capital	12.86	4.64	3.99	3.99
Preference Capital	0	0	0	0
Reserves	83.52	63.42	39.08	37.33
Net Worth	96.38	68.06	43.07	41.32
Minority Interest

Y/e 31 Mar( In .Cr)	Mar-2021	Mar-2020	Mar-2018	Mar-2017
Revenue	133.89	112.77	58.06	56.69
yoy growth (%)	18.72	94.2	2.41	33.96
Raw materials	-101.77	-80.14	-39.51	-37.17
As % of sales	76	71.06	68.04	65.57
Employee costs	-8.65	-8.94	-5.18	-4.91

Y/e 31 Mar( In .Cr)	Mar-2021	Mar-2020	Mar-2018	Mar-2017
Profit before tax	4.37	2.49	2.64	2.22
Depreciation	-2	-1.87	-1.28	-1.13
Tax paid	-1.19	-0.59	-0.89	-0.79
Working capital	7.41	38.35	2.4	0.25
Other operating items

Y/e 31 Mar	Mar-2021	Mar-2020	Mar-2018	Mar-2017
Growth matrix (%)
Revenue growth	18.72	94.2	2.41	33.96
Op profit growth	10.51	95.94	27.02	-14.89
EBIT growth	23.5	50.86	11.66	3.5
Net profit growth	5.92	8.62	22.66	33.46

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd SUNPHARMA	1,665.2	130.91	3,99,537.26	867.6	0.81	5,536.99	98.75
Zydus Lifesciences Ltd ZYDUSLIFE	1,205.6	35.29	1,21,311.57	1,405.2	0.25	3,172.6	156.19
Cipla Ltd CIPLA	1,499.9	32.61	1,21,119.62	1,038.4	0.57	3,444.92	346.41
Divis Laboratories Ltd DIVISLAB	4,549.75	76.67	1,20,781.57	531	0.66	2,259	507.93
Dr Reddys Laboratories Ltd DRREDDY	6,854.2	26.69	1,14,348.41	1,034.8	0.58	5,081.8	1,458.96

Derivatives

IPO

Mutual Funds

Nifty 50

Loans

Knowledge Center

News

IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Derivatives

IPO

Mutual Funds

Nifty 50

Loans

Knowledge Center

News

Disclaimer

Research Disclaimer

Twitter Disclaimer

Terms & Conditions

RBI Policy Update

CSR Policy

Sitemap

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Fredun Pharmaceuticals Ltd Share Price

Invest wise with Expert advice

Equities

Futures

Option